Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Evolocumab binds PCSK9, increasing low‐density lipoprotein cholesterol (LDL‐C) receptors and lowering LDL‐C. Target‐mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL‐C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363371/
https://www.ncbi.nlm.nih.gov/pubmed/27667740
http://dx.doi.org/10.1002/jcph.832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363371/
https://www.ncbi.nlm.nih.gov/pubmed/27667740
http://dx.doi.org/10.1002/jcph.832

Ejemplares similares